Amgen and Allergan submitted a Biologics License Application (BLA) to the FDA for ABP 798, a biosimilar rituximab referencing Rituxan.
Amgen and Allergan late Thursday announced the submission of a Biologics License Application (BLA) to the FDA for ABP 798, a biosimilar rituximab referencing Rituxan.
"The US filing for ABP 798 marks an important milestone for Amgen, as it affirms our commitment to providing high quality biosimilars that offer more life-altering biological treatment options and contribute to the sustainability of healthcare systems," said David M. Reese, MD, executive vice president of research and development at Amgen, in a statement. "We look forward to working with the FDA to bring ABP 798 to market."
Rituxan is a CD20-directed cytolytic antibody that is approved to treat multiiple diseases, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis with glucocorticoids, and rheumatoid arthritis (RA). While the companies did not say which indications it was pursuing in its statement, the companies referenced the first 4 indications, but not RA.
"We are excited about the progress that we've made to date through our partnership with Amgen, which includes the launch of the first 2 oncology therapeutic biosimilars in the US," said David Nicholson, PhD, chief research and development officer at Allergan. "With ABP 798, we look forward to the opportunity to continue to provide additional treatment options to patients suffering from serious illnesses."
Amgen has a total of 10 biosimilars in its portfolio, 3 of which have been approved by the FDA and 3 that are approved in the European Union (EU).
Amgen and Allergan are collaborating on 4 oncology biosimilar medicines, 2 of which have already been approved by the FDA.
The BLA submission includes analytical, pharmacokinetic and clinical data, as well as pharmacology and toxicology data generated in 2 clinical studies. The results of these studies confirmed no clinically meaningful differences between ABP 798 and Rituxan.
Last month at the American College of Rheumatology (ACR)’s 2019 meeting, researchers reported on a phase 1 and 3 study of ABP 798 in patients with RA.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.